Kidney scoring surveillance: predictive machine learning models for clear cell renal cell carcinoma growth using MRI.
Clear cell renal cell carcinoma
Decision tree
Von Hippel–Lindau
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
18
10
2023
accepted:
14
12
2023
revised:
11
12
2023
pubmed:
13
2
2024
medline:
13
2
2024
entrez:
12
2
2024
Statut:
ppublish
Résumé
Classification of clear cell renal cell carcinoma (ccRCC) growth rates in patients with Von Hippel-Lindau (VHL) syndrome has several ramifications for tumor monitoring and surgical planning. Using two separate machine-learning algorithms, we sought to produce models to predict ccRCC growth rate classes based on qualitative MRI-derived characteristics. We used a prospectively maintained database of patients with VHL who underwent surgical resection for ccRCC between January 2015 and June 2022. We employed a threshold growth rate of 0.5 cm per year to categorize ccRCC tumors into two distinct groups-'slow-growing' and 'fast-growing'. Utilizing a questionnaire of qualitative imaging features, two radiologists assessed each lesion on different MRI sequences. Two machine-learning models, a stacked ensemble technique and a decision tree algorithm, were used to predict the tumor growth rate classes. Positive predictive value (PPV), sensitivity, and F1-score were used to evaluate the performance of the models. This study comprises 55 patients with VHL with 128 ccRCC tumors. Patients' median age was 48 years, and 28 patients were males. Each patient had an average of two tumors, with a median size of 2.1 cm and a median growth rate of 0.35 cm/year. The overall performance of the stacked and DT model had 0.77 ± 0.05 and 0.71 ± 0.06 accuracies, respectively. The best stacked model achieved a PPV of 0.92, a sensitivity of 0.91, and an F1-score of 0.90. This study provides valuable insight into the potential of machine-learning analysis for the determination of renal tumor growth rate in patients with VHL. This finding could be utilized as an assistive tool for the individualized screening and follow-up of this population.
Identifiants
pubmed: 38347265
doi: 10.1007/s00261-023-04162-y
pii: 10.1007/s00261-023-04162-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1202-1209Informations de copyright
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Bausch B, Jilg C, Gläsker S, Vortmeyer A, Lützen N, Anton A, et al. Renal cancer in von Hippel–Lindau disease and related syndromes. Nature Reviews Nephrology. 2013;9(9):529-38.
doi: 10.1038/nrneph.2013.144
pubmed: 23897319
Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A review of Von Hippel-Lindau syndrome. Journal of Kidney Cancer and VHL. 2017;4(3):20.
doi: 10.15586/jkcvhl.2017.88
pubmed: 28785532
pmcid: 5541202
Rasmussen RG, Xi Y, Sibley III RC, Lee CJ, Cadeddu JA, Pedrosa I. Association of clear cell likelihood score on MRI and growth kinetics of small solid renal masses on active surveillance. AJR American journal of roentgenology. 2022;218(1):101.
doi: 10.2214/AJR.21.25979
pubmed: 34286596
Whelan EA, Mason RJ, Himmelman JG, Matheson K, Rendon RA. Extended duration of active surveillance of small renal masses: a prospective cohort study. The Journal of Urology. 2019;202(1):57-61.
doi: 10.1097/JU.0000000000000075
pubmed: 30932757
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(1):71–90.
Kim E, Zschiedrich S. Renal cell carcinoma in von hippel–lindau disease—from tumor genetics to novel therapeutic strategies. Frontiers in pediatrics. 2018;6:16.
doi: 10.3389/fped.2018.00016
pubmed: 29479523
pmcid: 5811471
Maher ER, Neumann HP, Richard S. von Hippel–Lindau disease: A clinical and scientific review. European Journal of Human Genetics. 2011;19(6):617-23.
doi: 10.1038/ejhg.2010.175
pubmed: 21386872
pmcid: 3110036
Jilg C, Neumann H, Gläsker S, Schäfer O, Ardelt P, Schwardt M, et al. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma. Urologia internationalis. 2012;88(1):71-8.
doi: 10.1159/000333348
pubmed: 22156657
Schuhmacher P, Kim E, Hahn F, Sekula P, Jilg CA, Leiber C, et al. Growth characteristics and therapeutic decision markers in von Hippel-Lindau disease patients with renal cell carcinoma. Orphanet journal of rare diseases. 2019;14(1):1-8.
doi: 10.1186/s13023-019-1206-2
Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. The Journal of urology. 2007;178(2):429-34.
doi: 10.1016/j.juro.2007.03.106
pubmed: 17561141
Kutikov A, Smaldone MC, Egleston BL, Manley BJ, Canter DJ, Simhan J, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol. 2011;60(2):241-8.
doi: 10.1016/j.eururo.2011.03.029
pubmed: 21458155
pmcid: 3124570
Gopal N, Anari PY, Chaurasia A, Antony M, Wakim P, Linehan WM, Ball M, Turkbey E, Malayeri A. The kidney imaging surveillance scoring system (KISSS): using qualitative MRI features to predict growth rate of renal tumors in patients with von-Hippel Lindau (VHL) syndrome. Abdom Radiol. 2024;49(2):542-50.
doi: 10.1007/s00261-023-04087-6
Xu Q-S, Liang Y-Z. Monte Carlo cross validation. Chemometrics and Intelligent Laboratory Systems. 2001;56(1):1-11.
doi: 10.1016/S0169-7439(00)00122-2
Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA, et al. Somatic mutations of the von Hippel—Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Human molecular genetics. 1994;3(12):2169-73.
doi: 10.1093/hmg/3.12.2169
pubmed: 7881415
Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. Journal of the National Cancer Institute. 1999;91(2):143-51.
doi: 10.1093/jnci/91.2.143
pubmed: 9923855
Chauveau D, Duvic C, Chrétien Y, Paraf F, Droz D, Melki P, et al. Renal involvement in von Hippel-Lindau disease. Kidney international. 1996;50(3):944-51.
doi: 10.1038/ki.1996.395
pubmed: 8872970
Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. The Lancet. 2003;361(9374):2059-67.
doi: 10.1016/S0140-6736(03)13643-4
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for renal cell carcinoma in von Hippel–Lindau disease. New England Journal of Medicine. 2021;385(22):2036-46.
doi: 10.1056/NEJMoa2103425
pubmed: 34818478
WALTHER MM, CHOYKE PL, GLENN G, LYNE JC, RAYFORD W, VENZON D, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. The Journal of urology. 1999;161(5):1475-9.
doi: 10.1016/S0022-5347(05)68930-6
pubmed: 10210376
McIntosh AG, Ristau BT, Ruth K, Jennings R, Ross E, Smaldone MC, et al. Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes. Eur Urol. 2018;74(2):157-64.
doi: 10.1016/j.eururo.2018.03.011
pubmed: 29625756
Choi SJ, Kim H-S, Ahn S-J, Park Y, Choi H-Y. Differentiating radiological features of rapid-and slow-growing renal cell carcinoma using multidetector computed tomography. Journal of Computer Assisted Tomography. 2012;36(3):313-8.
doi: 10.1097/RCT.0b013e3182506c26
pubmed: 22592616
Dodelzon K, Mussi TC, Babb JS, Taneja SS, Rosenkrantz AB. Prediction of growth rate of solid renal masses: utility of MR imaging features—preliminary experience. Radiology. 2012;262(3):884-93.
doi: 10.1148/radiol.11111074
pubmed: 22267588
Farhadi F, Nikpanah M, Paschall AK, Shafiei A, Tadayoni A, Ball MW, et al. Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel–Lindau Disease. Radiology. 2020;295(3):583.
doi: 10.1148/radiol.2020191016
pubmed: 32255415
Matsumoto R, Abe T, Shinohara N, Murai S, Maruyama S, Tsuchiya K, et al. RENAL nephrometry score is a predictive factor for the annual growth rate of renal mass. International Journal of Urology. 2014;21(6):549-52.
doi: 10.1111/iju.12388
pubmed: 24405437
Mehrazin R, Smaldone MC, Egleston B, Tomaszewski JJ, Concodora CW, Ito TK, et al., editors. Is anatomic complexity associated with renal tumor growth kinetics under active surveillance? Urologic Oncology: Seminars and Original Investigations; 2015: Elsevier.
Anari PY, Lay N, Gopal N, Chaurasia A, Samimi S, Harmon S, et al. An MRI-based radiomics model to predict clear cell renal cell carcinoma growth rate classes in patients with von Hippel-Lindau syndrome. Abdominal Radiology. 2022;47(10):3554-62.
doi: 10.1007/s00261-022-03610-5
pubmed: 35869307
Farhadi F, Nikpanah M, Paschall AK, Shafiei A, Tadayoni A, Ball MW, et al. Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel–Lindau Disease. Radiology. 2020;295(3):583-90.
doi: 10.1148/radiol.2020191016
pubmed: 32255415